Time to Go Shopping for Healthcare
The decline in equity markets has created opportunities to buy a variety of healthcare stocks at attractive valuations. Insider purchases have...
395 Views
Jiangsu Hengrui (1276 HK): 2025 Robust and Balanced, Innovative Drugs Hold Key to Future Growth
​Jiangsu Hengrui Pharmaceuticals sees 13% revenue rise in 2025, driven by innovative drugs sales, licensing revenue. Plans for over 30% growth from...
207 Views
Simcere Pharma (2096 HK): Sturdy 2025; Promising Pipeline, Approvals Will Take It Forward
​Simcere Pharma sees strong revenue growth driven by innovative products. Sanbexin injection increase market share in stroke treatment. Extensive...
267 Views
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
577 Views
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
605 Views